Last reviewed · How we verify
Aurora A kinase inhibitor MLN8237 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Aurora A kinase inhibitor MLN8237 (Aurora A kinase inhibitor MLN8237) — Mayo Clinic.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Aurora A kinase inhibitor MLN8237 TARGET | Aurora A kinase inhibitor MLN8237 | Mayo Clinic | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Aurora A kinase inhibitor MLN8237 CI watch — RSS
- Aurora A kinase inhibitor MLN8237 CI watch — Atom
- Aurora A kinase inhibitor MLN8237 CI watch — JSON
- Aurora A kinase inhibitor MLN8237 alone — RSS
Cite this brief
Drug Landscape (2026). Aurora A kinase inhibitor MLN8237 — Competitive Intelligence Brief. https://druglandscape.com/ci/aurora-a-kinase-inhibitor-mln8237. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab